醫藥新興市場區塊 3,000億美元市場規模!!!!!

生技醫療基金 題材多 2012/07/19 【經濟日報╱記者高佳菁／台北報導】 今年股市慘遭歐「傷」下挫，讓具備防禦色彩的生技醫療類股逆勢追漲，NBI生技指數今年以來上揚28.58%，7月初甚至一度逼近1,400點大關，隨著7月下旬生技股季報公布進入高峰，9月接著進入醫學年會及傳統旺季，加上併購題材不斷，相關生技醫療基金漲勢可期。ING全球生技醫療基金經理人黃靜怡表示，美國進入第2季財報公布期，生技類股走勢難免受財報表現左右，如本周有包含製藥大廠嬌生、亞培，以及醫療設備大廠百特醫療等企業將公布財報，7月下旬則有Biogen Idec、Amgen、Celgene等生技權值股加入行列，財報表現值得關注。富蘭克林坦伯頓生技領航基金經理人麥可羅指出，根據花旗集團預估，美國大型生技股2012～2014年獲利年增率預估值介於13%～15%，高於史坦普500大企業4%～6%增幅。黃靜怡認為，全球生技醫療類股產業基本面與總體經濟環境連動性偏低，在系統性風險升高之際，反而易吸引資金青睞；其次，今年上半年釋出之新藥研發結果，高達75%為正面，更重要的是9月開始進入醫學會議密集召開期，且第4季向來為生醫傳統產業旺季，預期下半年該類股仍可望震盪走高。德盛安聯全球生技大壩基金經理人傅子平進一步指出，近期市場偏重在具被購併條件與藥物研發和上市時程接近後段的公司，目前較看好此波大型製藥公司購併中小型生技公司的趨勢，預期在專利藥專利到期的壓力與低利率環境下，購併案將延燒至2013年。著眼新興市場受惠於中產階級成長、醫療涵蓋範圍擴張、每人藥品支出水準仍低、生活型態改變和慢性病增加等結構性因素，對醫療的需求成長潛力相當龐大，麥可羅認為，涵蓋金磚四國、南韓、土耳其與墨西哥等7國的醫藥新興市場的藥物支出占全球市場的比重，於2010年已正式超越歐洲5大國（法國、德國、義大利、西班牙、英國），成為僅次於美國的全球第2大支出區域，預估2015年醫藥新興市場的藥物支出金額有機會突破3,000億美元，成長潛力相當雄厚。

REVOLUTIONARY DRY SKIN TREATMENT SUCCESSFULLY OVERCOMES THE PROBLEM OF ECZEMA

 Saturday, 14 July 2012 Revolutionary dry skin treatment protects your skin from the itch of eczema.

What is the underlying cause of eczema? Eczema is a chronic skin disease characterized by dry, itchy, inflamed skin caused by an allergic immune response with in the skin. While there is no cure for the condition, understanding the causes and finding the right dry skin treatment product can greatly reduce the occurrence of symptomatic outbreaks and how to rejuvenate skin.

Could you be suffering from a damaged skin barrier? Nearly 80 percent of eczema is due to contact with harsh chemicals and environmental irritants. If you have damaged dry skin your skin's barrier is impaired and no longer properly functions and an increase in water loss having dry and cracked skin. Besides an increase in water loss, a damaged skin barrier makes your skin more susceptible to irritants that create an increased risk for dry skin conditions such as eczema. "As a dermatologist with many years of experience treating skin problems, I can tell you what the major causes are," says Dr. Lisa Benest, "one of them is exposure to irritants and chemicals in the everyday environment. We live in a much more toxic environment today and our skin bears the brunt. When we are exposed to harsh conditions in the environment it can have a very negative effect on our skin."

Shielding Lotion: A Revolutionary New Dry Skin Treatment that is the Best Lotion for Dry Skin Traditional moisturizers are simply add artificial moisture to the surface layer of your skin and do very little to heal or protect your skin. Many even contain harsh chemical ingredients that damage the integrity of your skin's barrier leading to more skin problems for you. Realizing the need for an entirely new approach to skin care, 21st Century Formulations put together a team of leading doctors, dermatologists, and cosmetic chemists who spent six years working together in developing Skin MD Natural Shielding Lotion. Skin MD Natural Shielding Lotion duplicates your skin's own natural functions and strengthens your skin's ability to protect against toxins and irritants resulting in healthier softer skin. Dr. Lisa Benest explains: "The reason shielding lotions are so effective is that they replace the protective barrier and allow the skin to heal from within. A shielding lotion bonds with the outer layer of the skin and protects it from outside irritants and chemicals, so it will prevent skin conditions from developing or it will help an existing condition to heal." Join the millions throwing away their old creams and lotions for Skin MD Natural: It's the only lotion that can truly treat severe eczema and is a real dry skin treatment. Go to http://www.skinmdnatural.com or call 800-540-4790 for more information. 21st Century Formulations is a company dedicated to creating healthy skin care shielding lotions. For more information please contact 1-800-540-4790. 

講究 "就診秩序 "的日本醫療體系 !

國際SOS：中國醫療品質仍待改進 台灣醒報實際入稿日期： 2012-07-19【台灣醒報記者劉運台北報導】中國及日本是台灣人近2年最喜歡旅遊的國家，但國人還是不熟悉國外的醫療制度。國際SOS緊急救援組織指出，即使中國的醫療體系持續改善，但是其人口眾多，仍然無法負荷廣大的人口需求，造成醫療品質的下降。相較之下，日本的醫療體系完善，國人比較可以放心就醫。國際SOS緊急救援組織指出，台灣人在國外就診主要是因為腸胃相關疾病、呼吸道相關疾病，及外傷（扭、挫、骨折）；最常就診的年齡層依序為36-55歲（43%），56-75歲（41%），16-35歲（14%）。在過去2年，最多國人前往的國家分別為中國（約58%）及日本（約13%）。 國際SOS緊急救援組織指出，即使中國一直在努力改善提升醫療品質，但中國的醫療體系仍然追不上中國廣大的人口需求。醫師陳琬琳指出，因為人滿為患，中國的醫院甚至出現VIP病房移至走廊上、病人的病床座位相隔距離太近，造成容易傳染疾病、沒有隱私的問題。另外，病房內環境欠佳、燈光昏暗，也會讓國人心生恐懼。 陳琬琳指出，中國的3級醫院硬體規模大、有幾千個床位，醫療人員也有一定的醫療水準，但也有許多缺失：由於中國人口眾多，經常有醫院門診大廳擠得水洩不通的情況，甚至有「門診黃牛」的現象，亦即有人提早來排隊領取號碼牌再轉而販售，價格是掛號費的5-6倍，若是名醫價碼則更高。 相較於中國，日本的醫療品質就讓人放心許多，但是有別於國人的看病習慣，日本的醫療體系非常講究「就診秩序」，看診有一定的流程。國人常把在台灣不好的看病習慣帶到日本，例如催促醫生、亂跑診間等問題。陳琬琳指出，如果去日本的醫院，應該多多注意，遵守當地的看病流程。

Current development of regenerative medicine products!!

Leading the way Business Posted on 18/07/2012 by Lorraine O'Hanlon @galwayindoThe global market potential for regenerative medicine products could be as high as $118 billion by 2013 and innovative Galway company Orbsen Therapeutics is working to target part of this rapidly expanding market, CEO Brian Molloy tells Lorraine O'Hanlon Earlier this year, US company Osiris Therapeutics received authorisation from the Canadian department of health to market its stem cell therapy Prochymal for the treatment of acute graft-versus-host disease in children who have received bone marrow transplants, marking the world's first regulatory approval of a manufactured stem cell product. Referring to the move as an important domino in the acceptance and development of stem cell therapies, Orbsen Therapeutics CEO Brian Molloy explains that adult stem cells appear to display an ability to combat inflammation and to promote healing and the repair and regeneration of tissue. "What that means is that if you have an inflammatory disease, for example rheumatoid arthritis, or when there's an inflammation of a particular organ or area of the body, stem cells seem to help calm down that inflammation" he says, adding that there are hundreds of ongoing trials across the world where stem cells are being used to treat a wide range of different conditions currently not being adequately treated by traditional drugs. There are currently up to 400 regenerative medicine products on the international market, with more in development. At NUI Galway, Orbsen Therapeutics is working on the development of an extensive range of therapies for conditions including osteoarthritis, acute respiratory distress syndrome and diabetes. Formed in 2006 to develop and commercialise new intellectual property built up by researchers at the Regenerative Medicine Institute (REMEDI), Orbsen has developed a novel proprietary technology enabling them to isolate pure and defined stromal cells, which it is hoped will allow the development of a range of human therapies. Led by Head of R&D Dr Stephen Elliman, the company is currently expanding rapidly and the number of employees is expected to increase to around ten by the end of the year. It is also hoped the company will begin clinical trials in 2014. The development of spin out companies from universities can be difficult, according to NUI Galway MBA graduate Mr Molloy, as a marrying of both business and scientific skills is required. He believes, however, that Orbsen is proving to be a "very good model for how you can bring university generated research into a commercial field by partnering up with commercial experts in the private field". Mr Molloy is a Director of financial advisory firm HC Financial Advisers, based in Oranmore. HC provide a range of business consultancy services to start-up and established firms and Mr Molloy serves as Orbsen Therapeutic's interim CEO under a business consultancy arrangement. NUI Galway remains a shareholder in the company and Mr Molloy explains that the business model for the privately owned company is very lean compared to the old style model of commercialisation of university developed spin outs, which would have involved "a very significant amount of capital being spent on getting the company up to a certain level of critical mass". He adds that it's much more difficult at the moment to source money than it had been in previous years, and that the focus now for start-up biotech companies such as Orbsen Therapeutics is really on keeping the operational costs as low as possible and "focus on the science". Despite the difficult economic climate, Orbsen's bids to secure funding over the years have proven very successful. The company will shortly commence a new round of fundraising and is currently seeking High Potential Start-Up status from Enterprise Ireland. The company has also secured significant EU funding and is lead SME on a EU Seventh Framework Programme (FP7) research initiative on diabetic complications. €6 million has been allocated to bring Orbsen's novel therapy to clinical trial in collaboration with leading researchers within NUI Galway and across Europe and the US. "There are a huge number of illnesses and conditions where having an anti-inflammatory and immunomodulating product is of massive importance, that's why billions are being spent by 'Big Pharma' and international biotech companies to develop into this space. "Orbsen is ideally positioned because we are in the process of securing our IP [intellectual property] around our subpopulation of cells, we are in compliance with the emerging future regulatory requirements with regard to purity and definition of our cell product and we're doing it at a relatively low cost whilst leveraging the really high quality research coming out of NUI Galway," he says, adding that two of REMEDI's directors, Prof. Timothy O'Brien and Prof. Frank Barry, are also directors at Orbsen."As well as a multi-billion euro market potential there is also the added value of knowing that if our product delivers as we hope it will, it has the potential to improve and save people's lives," says Mr Molloy.

 

期待 長期照護費用 可拿來抵稅 !!

長照費立委籲列特別扣除額2012-7-19〔記者施曉光／台北報導〕曹姓民眾在申報綜所稅時將中風癱瘓父親的長期照護費用列報扣除額，被國稅局認定非法定醫療院所就診費用，必須補稅，纏訟六年，近經大法官釋憲後認定國稅局違憲。國民黨立委陳學聖昨天召開記者會呼籲國稅局檢討，除現有的「身心障礙特別扣除額」外，也應立即研議「長期照護特別扣除額」。衛生署護理及健康照護組副組長蔡誾誾表示支持，強調現行法令的確沒有補助居家照護、非醫療機構支出，希望國稅局可以儘快試算稅額，把居家照護支出納入列舉扣除額範圍，減輕家屬負擔。